Locked nucleic acid-enhanced detection of 1100delC*CHEK2 germ-line mutation in Spanish patients with hematologic malignancies.
暂无分享,去创建一个
U. Lass | O. Landt | P. Bolufer | E. Barragán | J. Cervera | M. Sanz | M. Collado
[1] P. Twomey,et al. Unreliability of triglyceride measurement to predict turbidity induced interference , 2003, Journal of clinical pathology.
[2] C. Ballantyne,et al. Role of lipid and lipoprotein profiles in risk assessment and therapy. , 2003, American heart journal.
[3] David I. Smith,et al. Mutations in CHEK2 associated with prostate cancer risk. , 2003, American journal of human genetics.
[4] P. Gregersen,et al. Frequency of CHEK2*1100delC in New York breast cancer cases and controls , 2003, BMC Medical Genetics.
[5] J. Herman,et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. , 2002, Blood.
[6] G. Mufti,et al. Analysis of CHK2 in patients with myelodysplastic syndromes. , 2002, Leukemia research.
[7] Mogens Havsteen Jakobsen,et al. LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E. , 2002, Nucleic acids research.
[8] O. Kallioniemi,et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.
[9] S. Ogawa,et al. Mutations of Chk2 in primary hematopoietic neoplasms. , 2002, Blood.
[10] R. Eeles,et al. A robust method for detecting CHK2/RAD53 mutations in genomic DNA , 2002, Human mutation.
[11] F. Milliat,et al. Intralipid 10%: physicochemical characterization. , 2001, Nutrition.
[12] N. Mailand,et al. The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.
[13] R. Macdonald,et al. Relationship between turbidity of lipid vesicle suspensions and particle size. , 2001, Analytical biochemistry.
[14] Jing Chen,et al. Characterization of Tumor-associated Chk2 Mutations* , 2001, The Journal of Biological Chemistry.
[15] D. Valle,et al. Online Mendelian Inheritance In Man (OMIM) , 2000, Human mutation.
[16] S. Elledge,et al. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.
[17] G. Hortin,et al. Lipemia interference with a rate-blanked creatinine method. , 1997, Clinical chemistry.
[18] E Magid,et al. Biological variability in the concentration of serum lipids: sources, meta-analysis, estimation, and minimization by relative range measurements. , 1995, Journal of the International Federation of Clinical Chemistry.
[19] S. Marcovina,et al. Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B. , 1994, Clinical chemistry.
[20] J. Pearson,et al. Serum index identifies lipemic samples causing interference with bilirubin assay on Hitachi 717. , 1991, Clinical Chemistry.
[21] K. Ryder,et al. Graphical comparisons of interferences in clinical chemistry instrumentation. , 1986, Clinical chemistry.
[22] J. Ladenson,et al. Analytical Errors due to Lipemia , 1983 .
[23] J. Benítez,et al. The breast cancer low‐penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population , 2004, International journal of cancer.
[24] The Polish Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .
[25] C. Price,et al. Immunonephelometric and immunoturbidimetric assays for proteins. , 1983, Critical reviews in clinical laboratory sciences.